Mercury Laboratories Limited

538964

INE947G01011

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:59 28/06/2024 BST			5-day change	1st Jan Change
949.6 ^INR	+3.01%		+6.94%	-7.77%

05-28	Mercury Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
02-12	Mercury Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Mercury Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2020

August 07, 2020 at 03:17 pm

Mercury Laboratories Limited announced earnings results for the first quarter ended June 30, 2020. For the first quarter, the company announced total revenue was INR 133.851 million compared to INR 148.703 million a year ago. Net income was INR 9.607 million compared to INR 9.987 million a year ago. Basic earnings per share was INR 8.01 compared to INR 8.32 a year ago.

Latest news about Mercury Laboratories Limited

Mercury Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-28	CI
Mercury Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-12	CI
Mercury Laboratories Names COO	11-09	MT
Mercury Laboratories Limited Announces Promotion of Saurabh Mittal as Chief Operating Officer	11-08	CI
Mercury Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-08	CI
Mercury Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	05/05/23	CI
Mercury Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	13/02/23	CI
Mercury Laboratories Limited Approves Creation of New Facility for Manufacturing Small Volume Parenteral(SVPs) At Jarod	12/11/22	CI
Mercury Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	11/11/22	CI
Mercury Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	09/08/22	CI
Mercury Laboratories Limited Announces Resignation of Kinjal Khandelwal as Company Secretary and Compliance Officer	21/01/22	CI
Mercury Laboratories Limited Approves Appointment of Mr. Ashish Vasavada, as Chief Financial Officer	21/10/21	CI
Mercury Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	10/08/21	CI
Mercury Laboratories : Crisil Affirms FB+ Rating on Mercury Laboratories' Fixed Deposits; Outlook Stable	18/06/21	MT
Mercury Laboratories' : CFO Tenders Resignation	28/05/21	MT
Mercury Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	27/05/21	CI
Mercury Laboratories Limited Announces Resignation of Enu Khandelwal as CFO with Effect from June 22, 2021	27/05/21	CI
Mercury Laboratories Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	11/02/21	CI
Mercury Laboratories Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	06/11/20	CI
Mercury Laboratories Limited Appoints Janki R Shah as Director	30/09/20	CI
Mercury Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2020	07/08/20	CI
Mercury Laboratories Limited Appoints Enu Khandelwal as Chief Financial Officer	07/08/20	CI
Mercury Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2020	30/05/20	CI
Mercury Laboratories Limited Announces Resignation of Poornima Karwat as Independent Woman Director	30/05/20	CI
Mercury Laboratories Limited to Approve the Resignation of Poornima Karwat as A Woman Non-Executive Independent Director	20/05/20	CI

Chart Mercury Laboratories Limited

Duration

Period

More charts

Company Profile

Mercury Laboratories Limited is an India-based pharmaceutical company. The Company operates through the Pharmaceuticals Products segment. The Company is engaged in the manufacturing and export of a range of pharmaceutical items. The products of the Company are in the segment of gynecology and pediatrics. Its products include antibiotic, antifungal, and antiviral formulations; anti-inflammatory formulations; antimalarial formulations; digestive formulations; hypoglycemic formulations; multivitamin formulations; central nervous system formulations; gynec formulations; CVS formulations; cough and cold formulations; and miscellaneous formulations, among others. Its antibiotic, antifungal, and antiviral formulations include azithromycin tablets, azithromycin dispersible tablets, griseofulvin tablets, metronidazole tablets, and others. Its anti-inflammatory formulations include dexamethasone tablets, glucosamine sulphate tablets, dexamethasone sodium phosphate injection, and others.

Sector

Pharmaceuticals

Calendar

05/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
MERCURY LABORATORIES LIMITED	-7.77%	13.26M
MERCK KGAA	+7.39%	72.4B
KYOWA KIRIN CO. LTD.	+15.93%	8.98B
YUHAN CORPORATION	+17.59%	4.28B
SK BIOPHARMACEUTICALS CO., LTD.	-22.81%	4.28B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+25.93%	4.01B
INDIVIOR PLC	+4.64%	2.16B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+9.09%	1.95B
BETTA PHARMACEUTICALS CO., LTD.	-36.86%	1.9B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B